RESEARCH MONOGRAPH · KDC-MN-118

SkQ1 (Visomitin)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

60/100

Skulachev's TPP-targeted plastoquinone. Approved as eye drops in Russia, the rest is mostly preclinical

SkQ1 is the Russian mitochondrial-targeted antioxidant developed by Vladimir Skulachev's group at Moscow State University. Like MitoQ it uses the triphenylphosphonium cation strategy to concentrate redox-active payload in mitochondria, but the payload is plastoquinone (a plant-derived quinone) rather than ubiquinone. The hypothesis was that plastoquinone has a more favorable redox window and is less likely to flip from antioxidant to pro-oxidant behavior at high concentrations.

SkQ1 has a real but narrow approved-drug history. Marketed in Russia as Visomitin eye drops, it's approved for dry eye disease with some clinical trial backing. The Skulachev project ran systematic preclinical work showing lifespan extension and reduction in age-associated pathology in multiple animal species including mice, dogs, and fish, which is among the more striking preclinical aging programs in recent decades. The "SkQ Project" published an enormous quantity of mechanism and animal-model work in the 2008-2015 period.

The translation gap to systemic human use is substantial. Outside of the topical ophthalmic application, oral or systemic SkQ1 in humans has very thin published trial data. Some Russian work on aging-related conditions exists but is hard to assess from outside the Russian scientific community, and Western replication is essentially absent. The geopolitical situation hasn't helped knowledge exchange in either direction.

Mechanistically the TPP-targeting strategy is the same as MitoQ, with the plastoquinone payload arguably more chemically stable in its reduced form. The Skulachev "phenoptosis" framework (his theory that aging is a programmed mitochondrial cell death cascade) is more speculative than mainstream geroscience but the underlying mechanistic work is solid.

What we like: serious mitochondrial biology pedigree, real animal preclinical data including lifespan in multiple species, an approved ophthalmic application demonstrating that the chemistry works in humans for at least one indication. The basic science is good.

What we dont like is the systemic human translation gap. There's basically no Western RCT data on systemic SkQ1, and the Russian work isn't easy to evaluate at arm's length. As a research tool for mitochondrial mechanism work it's interesting, as a clinical-application compound for humans it's much earlier than its preclinical pedigree might suggest.

Sourcing: SkQ1 is available from specialty research-chemical suppliers, the TPP-plastoquinone chemistry is somewhat complex and pure material is more expensive than ubiquinone analogs. HPLC verification is essential for confirming structure. Visomitin ophthalmic product is the only approved formulation but is geographically limited.

Interesting compound, mostly for mitochondrial mechanism research right now.

Evidence: 50
Mechanism: 78
Reliability: 55
Safety: 70
Sourcing: 55
Value: 50
Signal: 55
Staying power: 60

Plain-language summary Intrigue 72 / 100

SkQ1 (Visomitin) is a mitochondria-targeted plastoquinone developed in Russia by Vladimir Skulachev. Approved as eye drops for dry eye in Russia. Concentrates antioxidant activity in mitochondria similar to MitoQ. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Mitochondria-targeted plastoquinone

A mitochondria-targeted plastoquinone developed by Vladimir Skulachev's group, marketed in Russia as Visomitin eye drops for dry eye disease.

Abstract

SkQ1 (10-(6'-plastoquinonyl)decyltriphenylphosphonium; CAS 902281-65-2) is a mitochondria-targeted antioxidant developed by Vladimir Skulachev's group at Moscow State University in the early 2000s as part of a research program on mitochondrial aging interventions. The compound is structurally analogous to MitoQ but uses plastoquinone (a related quinone from photosynthetic systems) as the antioxidant moiety. SkQ1 is approved in Russia as Visomitin eye drops for dry eye disease and age-related ocular surface disorders. Animal studies show extended lifespan in mice and reduced age-related pathology. The compound is also studied in cardiovascular and CNS aging applications. Pharmacokinetics: TPP+ cation chemistry similar to MitoQ; plasma half-life and tissue distribution characteristics parallel.

Mechanism of action

Mitochondria-targeted plastoquinone (TPP+ cation). Same mechanism class as MitoQ.

Reported research dose ranges

Eye drops at 0.155 microg/mL (Russian formulation).

References

Skulachev VP, et al. An attempt to prevent senescence: a mitochondrial approach. Biochim Biophys Acta 2009.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-118

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

SkQ1 (Visomitin)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs